Financial Performance - Net sales for the second quarter of fiscal 2026 increased by $1.9 million, or 11%, to $18.7 million compared to $16.8 million in the same period of fiscal 2025[3] - Gross profit for the second quarter increased by $671,000, or 13%, to $5.7 million, with a gross margin improvement of 1 percentage point to 31%[4] - Operating income for the second quarter rose by $567,000, or 21%, to $3.3 million, driven by higher sales and improved gross margins[6] - Net income for the second quarter was $2.2 million, or $0.66 per diluted share, compared to $2.0 million, or $0.61 per diluted share, in the prior year[6] - For the six months ended December 31, 2025, net sales increased by $5.5 million, or 17%, to $37.2 million from $31.7 million in the same period of fiscal 2025[7] - Gross profit for the six months increased by $889,000, or 9%, but gross margin decreased by 2 percentage points to 30% due to a less favorable product mix[8] - Operating income for the six months rose by $663,000, or 12%, to $6.4 million compared to $5.7 million in the prior year[10] - Net income for the six months was $6.9 million, or $2.07 per diluted share, compared to $4.5 million, or $1.33 per diluted share, in the same period of fiscal 2024[11] Strategic Initiatives - The company plans to complete an acquisition of a local machine shop, which will enhance manufacturing capacity and technology[12] - A three-year contract extension with the largest customer is expected to support future growth[12]

Sales Performance - Medical device product sales increased by $2.9 million, or 24%, for the three months ended December 31, 2025, and by $7.4 million, or 33%, for the six months ended December 31, 2025, compared to the prior fiscal year[99]. - Orthopedic sales rose by $2.6 million, or 27%, for the three months and by $6.9 million, or 43%, for the six months ended December 31, 2025, primarily due to the launch of a next-generation handpiece[99]. - Recurring revenue from CMF drivers increased by $1.3 million, or 69%, for the three months and by $1.9 million, or 47%, for the six months ended December 31, 2025[99]. - Thoracic sales decreased by $880,000, or 83%, for the three months and by $1.4 million, or 67%, for the six months ended December 31, 2025[99]. - Non-recurring and prototype revenue increased by $108,000, or 263%, for the three months and by $536,000, or 602%, for the six months ended December 31, 2025, due to an increase in billable contracts[100]. - Repair revenue decreased by $1.7 million, or 35%, for the three months and by $3.0 million, or 30%, for the six months ended December 31, 2025, attributed to fewer repairs of legacy orthopedic handpieces[101]. Financial Position - The company had a backlog of approximately $37.4 million as of December 31, 2025, with $32.5 million scheduled for delivery in fiscal 2026[102]. - Cash and cash equivalents increased to $8.0 million as of December 31, 2025, from $419,000 at June 30, 2025[113]. - Working capital as of December 31, 2025, was $37.0 million, with sufficient funds expected to meet cash requirements for at least the next 12 months[120]. Operating Expenses - Cost of sales for the three months ended December 31, 2025, increased by $1.2 million, or 10%, compared to the same period in the prior fiscal year, while revenue increased by 11%[103]. - Gross profit increased by $671,000, or 13%, for the three months ended December 31, 2025, with a gross margin of 31%, up 1 percentage point from the prior year[104]. - Operating expenses for the three months ended December 31, 2025, totaled $2.5 million, representing 13% of net sales, with general and administrative expenses increasing by $322,000[105]. - Research and development costs decreased by $208,000, or 22%, for the three months ended December 31, 2025, compared to the prior year, primarily due to shifts in project expenses[107]. Cash Flow - Net cash provided by operating activities was $5.9 million for the six months ended December 31, 2025, driven by net income of $6.9 million[115]. - Net cash generated from investing activities was $8.8 million, primarily from the proceeds of the Monogram investment[117]. - Net cash used in financing activities totaled $7.1 million, mainly due to principal payments on loans and share repurchases[118]. Strategic Initiatives - The company is actively pursuing the acquisition of a significant supplier to meet increased demand following a contract extension with its largest customer[95]. - The Helios driver for CMF applications, featuring adaptive torque-limiting software, is expected to be released for production later this fiscal year[96]. - The company continues to focus on expanding manufacturing capacity at the Franklin Property to support anticipated growth[98]. Taxation - The effective tax rate for the three months ended December 31, 2025, was 25%, up from 21% in the prior year[112].

Core Viewpoint - PRO-DEX, INC. reported its financial results for the second quarter of fiscal 2026, which ended on December 31, 2025, indicating the company's performance and financial health during this period [1] Financial Performance - The company announced its financial results for the second quarter of fiscal 2026 [1]

Group 1 - The article does not provide any specific insights or analysis related to companies or industries, focusing instead on the author's credentials and disclosures [1][2][3]

Group 1 - The article does not provide any specific insights or analysis related to companies or industries, focusing instead on the author's credentials and disclosures [1][2][3]

Core Viewpoint - Pro-Dex, Inc. (PDEX) manufactures surgical drivers and shavers primarily for orthopedic medical devices, with no significant changes in its situation over the past few years [1]. Group 1: Company Overview - Pro-Dex focuses on operational aspects and long-term earnings power rather than market-driven dynamics [1]. - The company is evaluated from a buy-and-hold perspective, indicating a long-term investment strategy [1]. Group 2: Investment Strategy - The investment approach emphasizes holding companies that are fundamentally strong, regardless of short-term price movements [1]. - Most investment calls are expected to be holds, reflecting a cautious stance in a bullish market [1].

Group 1 - Pro-Dex, Inc. (PDEX) manufactures surgical drivers and shavers primarily used in orthopedic medical devices [1] - The company's operational situation has not changed meaningfully over the years, indicating a consistent trend [1] - The investment approach focuses on long-only strategies, evaluating companies from an operational and buy-and-hold perspective [1] Group 2 - The articles emphasize understanding long-term earnings power and competitive dynamics within the industries [1] - Most recommendations are holds, reflecting a cautious approach in a relatively bullish market [1] - A small fraction of companies are considered suitable for a buy at any given time, highlighting selectivity in investment opportunities [1]

Core Viewpoint - PRO-DEX, INC. has executed a contract amendment with its largest customer, extending the agreement for an additional three years [1] Company Summary - The contract amendment was executed on December 17, 2025, indicating a strong relationship with the largest customer [1]

Core Insights - Long Cast Advisers reported a cumulative net return improvement of 4% in Q3 2025, with a total cumulative return of 266% net of fees since inception in November 2015, translating to a 14% CAGR [1] Company Summary - Pro-Dex, Inc. (NASDAQ:PDEX) is highlighted as a key stock in Long Cast Advisers' Q3 2025 investor letter, specializing in powered surgical instruments for medical device OEMs [2] - The stock of Pro-Dex, Inc. experienced a one-month return of 1.50% but has seen a significant decline of 25.65% over the past 52 weeks, closing at $36.44 per share with a market capitalization of $119.523 million as of November 28, 2025 [2] - Pro-Dex, Inc. issued a press release in mid-September addressing a significant stock decline, clarifying that it is not associated with a blockchain platform sharing the same ticker, and added a risk disclosure regarding potential AI-related errors affecting the stock [3]

Core Insights - Pro-Dex, Inc. (PDEX) reported quarterly earnings of $0.62 per share, exceeding the Zacks Consensus Estimate of $0.50 per share, but down from $0.75 per share a year ago, indicating an earnings surprise of +24.00% [1] - The company generated revenues of $18.53 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 21.11% and up from $14.89 million year-over-year [2] - Pro-Dex shares have declined approximately 34.3% year-to-date, contrasting with the S&P 500's gain of 17.2% [3] Earnings Outlook - The future performance of Pro-Dex's stock will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.59 on revenues of $17.3 million, and for the current fiscal year, it is $2.38 on revenues of $70 million [7] Industry Context - The Medical - Dental Supplies industry, to which Pro-Dex belongs, is currently ranked in the top 21% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]